These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23916726)

  • 1. Meeting commentary--"medicines for older adults: learning from practice to develop patient centric drug products".
    Wahlich J; Stegemann S; Orlu-Gul M
    Int J Pharm; 2013 Nov; 456(1):251-7. PubMed ID: 23916726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meeting commentary--"Parkinson's disease: From patient to product".
    Wahlich J; Elder D; Liu F; Hughes C; Orlu-Gul M
    Int J Pharm; 2015 Oct; 494(1):167-71. PubMed ID: 26248146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public engagement workshop: how to improve medicines for older people?
    Orlu-Gul M; Raimi-Abraham B; Jamieson E; Wei L; Murray M; Stawarz K; Stegemann S; Tuleu C; Smith FJ
    Int J Pharm; 2014 Jan; 459(1-2):65-9. PubMed ID: 24291080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal medication use in elders. Key to successful aging.
    Monane M; Monane S; Semla T
    West J Med; 1997 Oct; 167(4):233-7. PubMed ID: 9348752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical strategies towards optimising polypharmacy in older people.
    Hughes CM; Cadogan CA; Patton D; Ryan CA
    Int J Pharm; 2016 Oct; 512(2):360-365. PubMed ID: 26921516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geropharmacology: a primer for advanced practice acute care and critical care nurses, part I.
    Ferrario CG
    AACN Adv Crit Care; 2008; 19(1):23-35; quiz 36-7. PubMed ID: 18418102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel.
    Denneboom W; Dautzenberg MG; Grol R; De Smet PA
    Br J Gen Pract; 2006 Jul; 56(528):504-10. PubMed ID: 16834876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perils of polypharmacy: 10 steps to prudent prescribing.
    Carlson JE
    Geriatrics; 1996 Jul; 51(7):26-30, 35. PubMed ID: 8675045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of medicines for older adults: A personal perspective from industry.
    Hakes L
    Int J Pharm; 2016 Oct; 512(2):332-333. PubMed ID: 26688042
    [No Abstract]   [Full Text] [Related]  

  • 10. Alterations in drug disposition in older adults: a focus on geriatric syndromes.
    Maher D; Ailabouni N; Mangoni AA; Wiese MD; Reeve E
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):41-52. PubMed ID: 33078628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding medication errors in the elderly.
    Gupta M; Agarwal M
    N Z Med J; 2013 Nov; 126(1385):62-70. PubMed ID: 24217592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy considerations in elderly adults.
    Wooten JM
    South Med J; 2012 Aug; 105(8):437-45. PubMed ID: 22864103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An industrial perspective on the design and development of medicines for older patients.
    Page S; Coupe A; Barrett A
    Int J Pharm; 2016 Oct; 512(2):352-354. PubMed ID: 27001530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geriatric drug therapy: neglecting the inevitable majority.
    Stegemann S; Ecker F; Maio M; Kraahs P; Wohlfart R; Breitkreutz J; Zimmer A; Bar-Shalom D; Hettrich P; Broegmann B
    Ageing Res Rev; 2010 Oct; 9(4):384-98. PubMed ID: 20478411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of medication review and cognitive behaviour treatment by community pharmacists of patients discharged from the hospital on drug related problems and compliance: design of a randomized controlled trial.
    Ahmad A; Hugtenburg J; Welschen LM; Dekker JM; Nijpels G
    BMC Public Health; 2010 Mar; 10():133. PubMed ID: 20230611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards better understanding of patient centric drug product development in an increasingly older patient population.
    Stegemann S
    Int J Pharm; 2016 Oct; 512(2):334-342. PubMed ID: 26807529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from a preliminary review of scientific evidence for appropriateness of preparations, dosage forms and other product design elements for older adult patients.
    Messina R; Becker R; van Riet-Nales DA; Stegemann S
    Int J Pharm; 2015 Jan; 478(2):822-8. PubMed ID: 25445516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes.
    Gnjidic D; Le Couteur DG; Kouladjian L; Hilmer SN
    Clin Geriatr Med; 2012 May; 28(2):237-53. PubMed ID: 22500541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing patient-centric medicines for older people: Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population.
    van Riet-Nales DA; Sundberg K; de Boer A; Hirschlérova B
    Br J Clin Pharmacol; 2020 Oct; 86(10):2008-2013. PubMed ID: 32830323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Medical Directors Association and American Society of Consultant Pharmacists joint position statement on the Beers List of Potentially Inappropriate Medications in Older Adults.
    Swagerty D; Brickley R; ;
    J Am Med Dir Assoc; 2005; 6(1):80-6. PubMed ID: 15871879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.